Efficacy of FOLFOX4 regimen systemic chemotherapy in treating advanced hepatocellular carcinoma：An analysis of 22 cases
Abstract：Objective To evaluate the efficacy of FOLFOX4 regimen systemic chemotherapy in treating advanced hepatocellular carcinoma (HCC). Methods The clinical data of 22 cases of advanced HCC were treated by FOLFOX4 regimen systemic chemotherapy between July 2007 and July 2013 in the First Affiliated Hospital of Sun Yat-sen University were analyzed retrospectively. The chemotherapy was given each two weeks,with a maximum of 8 cycles. The therapeutic responses were evaluated each 3 cycles and end of treatment. Results A total of 85 cycles were administered in 22 cases,with a mean of(3.7±2.0)cycles/case. There were no complete response,5 partial responses,5 static diseases and 12 progressive diseases. The objective response rate was 22.7%(5/22),and disease control rate was 45.4%(10/22),with a one-year survival rate of 12.1%and median survival time of 5.8 months in the follow up of 2-34 (8.5±1.9)months . In 10 cases of disease control after chemotherapy,the median survival time reached up to 9.5 months. Conclusion FOLFOX4 regimen systemic chemotherapy is effective in part of advanced HCC,and represented as an effective modality.
Keywords：hepatocellular carcinomaadvanced stagechemotherapyFOLFOX4 regimen
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 762-764 )